title: Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease.
abstract: Several beneficial effects of resveratrol (RES), a natural antioxidant present in red wine have already been described. The aim of our study was to investigate if RES had a clinically measurable cardioprotective effect in patients after myocardial infarction. In this double-blind, placebo controlled trial 40 post-infarction Caucasian patients were randomized into two groups. One group received 10 mg RES capsule daily for 3 months. Systolic and diastolic left ventricular function, flow-mediated vasodilation (FMD), several laboratory and hemorheological parameters were measured before and after the treatment. Left ventricular ejection fraction showed an increasing tendency (ns) by RES treatment. However, left ventricular diastolic function was improved significantly (p < 0.01) by RES. A significant improvement in endothelial function measured by FMD was also observed (p < 0.05). Low-density lipoprotein (LDL) level significantly decreased (p < 0.05) in the RES treated group. Red blood cell deformability decreased and platelet aggregation increased significantly in the placebo group (p < 0.05), while resveratrol treatment has prevented these unfavourable changes. Concerning other measured parameters no significant changes were observed neither in placebo nor in RES group. Our results show that resveratrol improved left ventricle diastolic function, endothelial function, lowered LDL-cholesterol level and protected against unfavourable hemorheological changes measured in patients with coronary artery disease (CAD).
authors.affiliation: 1st Department of Medicine, University of Pecs, Medical School, Pecs, Hungary.
authors.forename: K
authors.initials: K
authors.lastname: Magyar
authors.forename: R
authors.initials: R
authors.lastname: Halmosi
authors.forename: A
authors.initials: A
authors.lastname: Palfi
authors.forename: G
authors.initials: G
authors.lastname: Feher
authors.forename: L
authors.initials: L
authors.lastname: Czopf
authors.forename: A
authors.initials: A
authors.lastname: Fulop
authors.forename: I
authors.initials: I
authors.lastname: Battyany
authors.forename: B
authors.initials: B
authors.lastname: Sumegi
authors.forename: K
authors.initials: K
authors.lastname: Toth
authors.forename: E
authors.initials: E
authors.lastname: Szabados
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D001916:Brachial Artery / Q000187:drug effects / Q000473:pathology; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D004907:Erythrocyte Deformability / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D010919:Placebos; D010974:Platelet Aggregation / Q000187:drug effects; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000975:Antioxidants; D010919:Placebos; D013267:Stilbenes; D000077185:Resveratrol